Related Experiment Video
Updated: Jun 6, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Study on mitogenic activity of serum from patients with total coronary occlusions: relation to duration of occlusion
V Tchaikovski1,2, G S Werner3, M Fritzenwanger3
1Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Hospital, Maastricht University, Maastricht, The Netherlands.
Insights
Human serum mitogenic activity peaks 1-3 months after total coronary occlusion, correlating with collateral development. This finding highlights a critical window for potential therapeutic interventions to enhance blood vessel growth.
Area of Science:
- Cardiovascular Biology
- Angiogenesis Research
- Human Physiology
Background:
- Limited human data exist on vascular growth factors and collateral function in total coronary occlusions (TCOs).
- Understanding factors influencing collateral development is crucial for cardiovascular health.
- This study investigates the mitogenic potential of serum in relation to TCO duration.
Discussion:
- Serum mitogenic activity in TCO patients exhibits a time-dependent profile.
- Maximal mitogenic potential was observed between 1 and 3 months post-occlusion.
- This timeframe aligns with the period of most robust collateral circulation development.
Key Insights:
- Serum from patients with 1-3 month old TCOs is significantly more mitogenic than from those with shorter or longer occlusion durations.
- No correlation was found between mitogenic activity and demographic or clinical factors.
- The study identifies a specific time-dependent mitogenic profile in TCO patients.
Outlook:
- The identified time-window (1-3 months) is critical for potential therapeutic interventions targeting collateral growth.
- Further research could explore specific growth factors responsible for this enhanced mitogenic activity.
- Investigating methods to modulate this activity could lead to improved outcomes for patients with coronary artery disease.
Abstract:
In contrast to the extensive evidence from animal studies, only few human data are available on the relation of vascular growth factors and collateral function as well as on the conditions which may modify their release or function. In 31 patients with total coronary occlusion (TCOs) blood was collected from distal to the occlusion site (collateral circulation) and from the aortic root (systemic circulation). Serum was used to assess its mitogenic potential in [3H]-thymidine incorporation assay on human umbilical vein endothelial cells. Serum from patients with the duration of occlusion between 1 and 3 months was significantly more mitogenic as compared to either shorter or longer duration of occlusion. None of the demographic or clinical factors correlated with the mitogenic activity of serum. Serum from patients with TCOs shows a particular time-dependent mitogenic profile with a maximal activity between 1 and 3 months following the occlusion. This profile corresponds to the experimentally described time-line of strongest collateral development and indicates the time-window for possible modification.
